Amicus Therapeutics
FOLD
FOLD was delisted on the 24th of April, 2026.
200 hedge funds and large institutions have $3.53B invested in Amicus Therapeutics in 2018 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 67 increasing their positions, 65 reducing their positions, and 33 closing their positions.
439% more call options, than puts
Call options by funds: $74.3M | Put options by funds: $13.8M
10% more funds holding in top 10
Funds holding in top 10: 10 → 11 (+1)
5% more capital invested
Capital invested by funds: $3.37B → $3.53B (+$167M)
3% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 65
0.46% less ownership
Funds ownership: 120.54% → 120.08% (-0.46%)
3% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 33
1% less funds holding
Funds holding: 203 → 200 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$63M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$18.2M |
| 3 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$16.3M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$14.6M |
| 5 |
BlackRock
New York
|
+$14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
-$33M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$21.8M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$12.7M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$11.3M |
| 5 |
D.E. Shaw & Co
New York
|
-$10.5M |
FOLD Hedge Fund Activity: Q2 2018 in Review
200 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q2 2018, worth a combined $3.53B — up 4.9% from $3.37B a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of FOLD and 32 opened new positions — a net loss of 1 holder — while 65 trimmed existing stakes and 67 added.
The largest buyer was Morgan Stanley, adding an estimated $63M. The largest seller was Wells Fargo, cutting an estimated $33M.
- 200 institutional investors held Amicus Therapeutics (FOLD) as of Q2 2018, down from 203 in Q1 2018.
- Funds reported $3.53B of Amicus Therapeutics stock for Q2 2018, up 4.9% quarter-over-quarter.
- 32 funds opened new Amicus Therapeutics positions in Q2 2018 and 33 closed out, a net change of -1 holder.
- The largest Amicus Therapeutics buyer in Q2 2018 was Morgan Stanley, an estimated $63M added.
- The largest Amicus Therapeutics seller in Q2 2018 was Wells Fargo, an estimated $33M sold.
Based on aggregated 13F filings for Q2 2018.